single5MG
Cagrilintide
5MG Protocol
Cagrilintide 5MG
Injection Freq.
Once weekly on a consistent day.
Cycle Sched.
Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate)
Reconstitution
3.0 mL BAC water
Clinically observed body-weight reduction at higher weekly doses
Greater weight loss when combined with semaglutide (CagriSema) in trials
Dose-dependent efficacy (higher doses linked to greater weight loss)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 0.6 mg | 36 |
| 2 | Weeks 3–4 | 1.2 mg | 72 |
| 3 | Weeks 5–6 | 2.4 mg | 144 |
| 4 | Weeks 7–16 | 4.5 mg | 270 |
Once weekly on a consistent day.
Weekly subcutaneous injections for 12–16 weeks (or longer as appropriate)
Cagrilintide is described as a long-acting amylin analog engineered to sustain the appetite- and intake-reducing physiology of native amylin. In the protocol’s mechanism section, amylin signaling is linked to increased satiation, delayed gastric emptying, and suppression of postprandial glucagon secretion. Cagrilintide is positioned as acting at central amylin receptors in the hindbrain (including the area postrema), which influences appetite regulation and meal-size control. The formulation is modified with lipid/acylation chemistry to prolong residence time, yielding a multi-day half-life on the page (roughly 160–195 hours). This pharmacokinetic extension is the primary reason it can be administered on a weekly schedule in clinical research. Mechanistically, it can be summarized as durable central satiety signaling paired with slowed gastric transit.
Nausea
Vomiting
Diarrhea
Constipation
Injection-site redness/irritation
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)